IVAX in China
Executive Summary
Signs a letter of intent to acquire a 51% stake in a Chinese pharmaceutical factory (Baker-Norton-China Pharmaceutical Company), based in Yunan, China. The company will produce and market "a wide range of immediate and controlled release tablets and capsules as well as a line of pediatric and dermatologic products" for domestic use and Artmetheri, an anti-malarial drug, of which 70% will be exported. Pending finalization of the agreement, IVAX will contribute $ 750,000 in cash and technical expertise to the deal....
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth